Role of Topical Tranexamic Acid in Total Hip Arthroplasty

Inclusion Criteria: * 18-80 years of age. * Male or female. * Degenerative joint disease of hip joint. * Primary uncemented total hip arthroplasty. * Willingness to participate in the study, follow up at regular intervals Exclusion Criteria: * Known allergy to tranexamic acid * History of any acquired disturbances of color vision * Preoperative anemia on basis of pre-operative lab work up (a hemoglobin value of \<11 g/dL in females and \<12 g/dL in males) * History of previous myocardial infarction * History of arterial or venous thromboembolic disease * History of fibrinolytic disorders requiring intraoperative antifibrinolytic treatment, coagulopathy in the past and/or as identified by a preoperative platelet count of \<150,000/mm3, an international normalized ratio of \>1.5, or a prolonged partial thromboplastin time * Pregnancy (h/o any missed menstrual periods in a women of reproductive age group) * Breastfeeding * Refusal of blood products * Preoperative use of anticoagulant therapy within five days before surgery * Medical issues that may pose complications for surgery and would disqualify patient for surgery regardless of clinical trial (e.g. renal and hepatic failure) * Major comorbidities (e.g. severe ischemic heart disease ) * Severe pulmonary disease * Preoperative blood donation * Participation in another clinical trial involving pharmaceutical drugs